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Potentiation of the Antiproliferative Activity of Brequinar Sodium for 
Murine Lymphocytes by Exogenous Cytidine 
A.W. Thomson, J. Woo, B. Lemster, S. Todo, J.J. Fung, and T.E. Starzl 
THE antimetabolite brequinar sodium (BQR) is a novel quinoline carboxylic acid analogue with broad anti-
tumor activity in mice, including inhibition of the growth of 
tumor xenografts. I The mechanism of action of BQR in 
tumor cells is believed to involve inhibition of dihydrooro-
tate dehydrogenase, a step in de novo pyrimidine biosyn-
thesis,2.3 resulting in depletion of precursors required for 
RNA and DNA synthesis. There is recent evidence that 
BQR is very effective either alone or in combination with 
FK 506 or cyclosporine (Cy A) in the prolongation of 
experimental allograft or xenograft survival.4 To obtain 
more information on the influence of BQR on T - and B-cell 
activation and proliferation, we have investigated its ef-
fects on the responses of murine spleen cells to various 
stimulants, including concanavalin A (ConA), phorbol 
myristate acetate (PMA) ± ionomycin, anti-CD3, and 
anti-Igs. Since BQR inhibits pyrimidine biosynthesis. we 
have also determined the effects of exogenous uridine and 
cytidine on the antilymphocytic activities of the drug in 
vitro. 
MATERIALS AND METHODS 
Reagents 
BQR (DuPont Merck Pharmaceutical Co. Wilmington. Dell was 
kindly provided by Dr L. Makowka. Cedars-Sinai Medical Center 
(Los Angeles. Calif). It was dissolved fresh before each experi-
ment in sterile saline (1 mg/mL) and diluted in RPMI-I640 (Gibco. 
Grand-Island, NY). ConA, PMA. ionomycin, uridine, cytidine. 
and goat anti-mouse Igs were from Sigma Chemical Co (St Louis. 
Mo). Antimurine CD3 monoclonal antibody (MAb; clone KT3) 
was from Serotec (Oxford, England, UK). 
Lymphocyte Culture 
Nucleated spleen cells isolated from spleens of 8- to 12-week-old. 
male C57BUIO SnJ mice (Jackson Laboratory, Bar Harbor. Me) 
were prepared as described previously~ in RPMI-I640 with 10% 
vol/vol fetal bovine serum (FBS) and 5 x 105 cells added to 
triplicate round-bottom wells of 96-well microtiter plates (Corn-
ing. NY). Cells were stimulated with ConA <0.5 to 5 J,Lg/mL). PMA 
(1 ng/mL). ionomycin (0.5 J,LmoIlL). anti-CD3 (I of 100). or anti-Ig 
(I of 50) for 24 to 120 hours. For estimation of DNA synthesis. 1 
J,LCi 3H-thymidine was added 24 hours before harvest and incor-
poration of radioactivity into DNA estimated by liquid scintilla-
tion counting. 
Quantitation of Cytokine Production and Cytokine 
Gene Expression 
Interleukin-2 (lL-2) and IL-4 levels in supernatants of cultures of 
50 x 106 spleen cells stimulated for 20 hours with ConA (5 JLg/mL) 
in Falcon tissue culture tubes were estimated using enzyme-linked 
immunosorbent assay (ELISA) kits for murine IL-2 (Collabora-
tive Research Inc. Bedford. Mass) or IL-4 (Endogen Inc. Boston. 
Mass). Production of mRNA for IL-2 and IL-4 in ConA-stimu-
lated cells was determined by semiquantitative reverse transcrip-
tion polymerase chain reaction as described elsewhere.6 
RESULTS AND DISCUSSION 
In 72-hour cultures, addition of BQR (5 JLg/mL to 0.1 
JLg/mL) at 0 hour caused dose-dependent inhibition of the 
strong proliferative responses induced by both ConA (5 
JLg/mL) (Fig ta) and PMA + ionomycin (data not shown). 
In contrast, no impairment oflow concentration ConA (0.5 
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Fig 1. Effects of exogenous nucleosides on the anti proliferative 
activity of BaR. (8) The inhibitory effect of BaR on ConA (5 
ILQImL)-stimulated DNA synthesis was reversed by undine but 
potentiated by cytidine. (b) Inhibition of weaker anti-CD3-induced 
DNA synthesis by BaR + cytidine but not by BaR alone. (c) 
Inhibition of anti-Ig-induced DNA synthesis by BaR + cytidine but 
not by BaR alone. 
705 
or 0.1 ~g/miFK anti-CD3. or anti-Ig responses was ob-
served. 
Addition of BQR to ConA (5 ~g/miF cultures as late as 
24 hours gave 70% inhibition of DNA synthesis. The 
capacity of synthetic nucleosides to reverse the inhibitory 
effect of BQR was examined by addition of either uridine 
(0.1 mmollL) or cytidine (0.1 mmollL) together with BQR 
at the start of ConA-. anti-CD3-. or anti-Ig-stimulated 
cultures. Uridine almost totally reversed the inhibitory 
effect of BQR. whilst in contrast. cytidine potentiated its 
action (Fig la~FK Cytidine alone had a modest inhibitory 
effect on ConA-stimulated DNA synthesis. These obser-
vations are consistent with inhibition by BQR of a step in 
de novo pyrimidine nucleotide biosynthesis. Moreover. 
they suggest that ConA-stimulated murine lymphocytes 
may lack cytidine deaminase. which permits formation of 
uridine or its anabolites from cytidine (salvage pathway). 
ConA (5 ~g/miF-stimulated lymphocytes cultured for 24 
hours in the presence of BQR (5 ~g/miF showed no 
inhibition of production of mRNA for IL-2 or IL-4 or of 
cytokine production. 
Combination of BQR with cytidine inhibited IL-2 and 
IL-4 production but not mRNA expression (data not 
shown). The observed antimetabolic effects of BQR com-
plement the cytokine synthesis inhibitory action of FK 506 
or Cy A and suggest that this new agent may prove useful 
as adjunctive immunosuppressive therapy in combination 
with either FK 506 or CyA. Moreover. combination of 
BQR and cytidine may offer a further possibility for 
inhibition of T - and B-ceU proliferation. 
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